Research Article
Development and Validation of an RP-HPLC Method for CB13 Evaluation in Several PLGA Nanoparticle Systems
Table 3
Optimized formulations: influence of production method () (initial amount of CB13 (6% w/w).
| | Method | (nm) | ZP (mV) | EE ± SD (%) | Drug loading (%w/w) |
| | SEV-US | 420.30 ± 215.43 | −29.5 ± 1.9 | 69.54 ± 0.34 | 4.172 ± 0.45 | | SEV-FF | 990.61 ± 10.90 | −25.6 ± 3.2 | 92.87 ± 0.96 | 5.572 ± 0.39 | | NPP | 320.73 ± 108.02 | −24.5 ± 2.3 | 85.69 ± 0.940 | 5.141 ± 0.67 |
|
|
